A pot of money to give cancer patients access to expensive lifeextending drugs is about to get controversial The Cancer Drugs Fund in England is certainly popular with patients  too popular in fact  This week it will be culling some of the drugs it funds because  The move has already angered some raised questions about how the NHS pays for innovative new drugs and led to calls for the fund to be scrapped entirely The National Institute for Health and Care Excellence NICE approves drugs for widespread use in the NHS It is prepared to fork out up to  for a course of drugs to extend life by a year adjusted to take account of the quality of life achieved  It will pay around double that for endoflife drugs including those for cancer Yet the latest wave of cancer medicines are coming with hefty price tags some costing  per qualityadjusted life year to use the technical jargon In a moment of election campaigning in  the now Prime Minister David Cameron proposed a Cancer Drugs Fund a mayear pot of money to pay for these superexpensive drugs The fund was supposed to expire last year but has been extended until  It has been great for eligible patients Around  have used the scheme some will have gained months or even years of life through drugs which the NHS could never normally afford Yet it divides loyalties as Dr Mangesh Thorat a cancer doctor at Queen Mary University of London has argued This issue presents me with a dilemma  as a cancer clinician I am happy that this Cancer Drugs Fund prevents my patients from being denied treatments towards the end of their life However on the other hand I think this fund not only undermines NICE but also discriminates against patients in similar situations who have diseases other than cancer The Cancer Drugs Fund is about to introduce pricecaps on the drugs it will fund The pharmaceutical industry has already been told some of their drugs  including Jevtana Zaltrap and Halaven  are being pulled as a result There will inevitably be outrage in some quarters when the announcement  expected Monday or Tuesday  is made  The Association of the British Pharmaceutical Industry has already said it would deplore any decision to restrict or remove patient access to cancer medicines Yet there is a much more fundamental conundrum that needs addressing The Cancer Drugs Fund is a sticking plaster  it exists because the old system no longer works So how does the industry make a profit out of drugs that are often taken for just a few months while the NHS gets a price it can afford Breakthrough Breast Cancer describes the Cancer Drugs Fund as a shortterm fix for a longterm problem adding that the longterm solution is now long overdue All eyes are on the governments   which is expected to report before the Autumn 